GSK (NYSE:GSK) Stock Keeps “Buy” Rating at Berenberg Bank

by · The Markets Daily

Berenberg Bank reaffirmed their buy rating on shares of GSK (NYSE:GSK – Free Report) in a report issued on Tuesday.

Other research analysts have also issued reports about the stock. Wolfe Research assumed coverage on shares of GSK in a report on Friday. They set an “outperform” rating and a $70.00 price objective for the company. Jefferies Financial Group raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 17th. Citigroup initiated coverage on GSK in a research note on Friday, July 24th. They issued a “neutral” rating for the company. HSBC reissued a “hold” rating on shares of GSK in a report on Thursday, September 10th. Finally, Weiss Ratings downgraded GSK from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, July 29th. Four analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $55.33.

Get Our Latest Analysis on GSK

GSK Trading Down 0.1%

Shares of GSK stock traded down $0.04 on Tuesday, reaching $46.49. 8,542,712 shares of the stock were exchanged, compared to its average volume of 4,225,426. The stock has a market cap of $94.05 billion, a P/E ratio of 14.54, a price-to-earnings-growth ratio of 2.09 and a beta of 0.33. The company has a quick ratio of 0.52, a current ratio of 0.82 and a debt-to-equity ratio of 0.81. The firm has a 50 day moving average of $50.02 and a two-hundred day moving average of $51.83. GSK has a 1-year low of $42.85 and a 1-year high of $61.69.

GSK (NYSE:GSK – Get Free Report) last issued its earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.09. GSK had a return on equity of 43.23% and a net margin of 14.56%. The firm had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.02 billion. During the same quarter last year, the firm earned $0.47 earnings per share. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. On average, research analysts anticipate that GSK will post 4.78 EPS for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 8th. Investors of record on Friday, August 14th were given a dividend of $0.4515 per share. The ex-dividend date of this dividend was Friday, August 14th. This represents a $1.81 dividend on an annualized basis and a dividend yield of 3.9%. This is a boost from GSK’s previous quarterly dividend of $0.44. GSK’s payout ratio is currently 55.31%.

Hedge Funds Weigh In On GSK

Large investors have recently bought and sold shares of the business. Security National Bank of SO Dak acquired a new stake in shares of GSK during the 2nd quarter worth approximately $38,000. Trust Co. of Vermont bought a new stake in GSK in the second quarter valued at $54,000. Philadelphia Investment Partners LLC acquired a new position in shares of GSK during the second quarter valued at $70,000. Ancora Advisors LLC bought a new position in shares of GSK during the second quarter worth about $71,000. Finally, Bogart Wealth LLC grew its position in shares of GSK by 15.3% during the first quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock worth $83,000 after acquiring an additional 200 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Company Profile

(Get Free Report)

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company develops and commercializes medicines and vaccines, with research and commercial activities focused on infectious diseases, respiratory conditions, immunology, oncology and HIV. Its products are distributed across markets worldwide through healthcare providers, public health systems and pharmacies.

GSK’s portfolio includes vaccines such as Shingrix for shingles and Arexvy for respiratory syncytial virus (RSV), as well as specialty medicines including Trelegy for chronic respiratory disease and Nucala for severe asthma and related inflammatory conditions.

See Also